Volume 69, Issue 5 pp. 595-598
Short Communication: Hepatology

Shortened 8-Week Course of Sofosbuvir/Ledipasvir Therapy in Adolescents With Chronic Hepatitis C Infection

Daniele Serranti

Corresponding Author

Daniele Serranti

Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, Firenze

Address correspondence and reprint requests to Daniele Serranti, MD, Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, Firenze, Italy, Viale Gaetano Pieraccini 24, Firenze 50139, Italy (e-mail: [email protected]).Search for more papers by this author
Icilio Dodi

Icilio Dodi

Pediatria Generale e d’Urgenza, Ospedale dei Bambini “Pietro Barilla”, Azienda Ospedaliero-Universitaria di Parma, Parma

Search for more papers by this author
Emanuele Nicastro

Emanuele Nicastro

Paediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII, Bergamo

Search for more papers by this author
Antonina M. Cangelosi

Antonina M. Cangelosi

Pediatria Generale e d’Urgenza, Ospedale dei Bambini “Pietro Barilla”, Azienda Ospedaliero-Universitaria di Parma, Parma

Search for more papers by this author
Silvia Riva

Silvia Riva

Unità di Epatologia Pediatrica e Trapianto di Fegato ISMETT Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo

Search for more papers by this author
Silvia Ricci

Silvia Ricci

Immunology Division, Section of Pediatrics, Department of Health Sciences, University of Florence and Meyer Children's University Hospital of Florence, Firenze

Search for more papers by this author
Elisa Bartolini

Elisa Bartolini

Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, Firenze

Search for more papers by this author
Sandra Trapani

Sandra Trapani

Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, Firenze

Search for more papers by this author
Greta Mastrangelo

Greta Mastrangelo

Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, Firenze

Search for more papers by this author
Pietro Vajro

Pietro Vajro

Dipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitana”, Università di Salerno, Salerno, Italy

Search for more papers by this author
Lorenzo D'Antiga

Lorenzo D'Antiga

Paediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII, Bergamo

Search for more papers by this author
Massimo Resti

Massimo Resti

Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, Firenze

Search for more papers by this author
Giuseppe Indolfi

Giuseppe Indolfi

Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, Firenze

Search for more papers by this author
First published: 01 November 2019
Citations: 17

The authors did not receive any financial support for this article. The authors did not receive any financial support by the National Institutes of Health (NIH), the Wellcome Trust, and the Howard Hughes Medical Institute (HHMI).

D.S., G.I., E.N., and L.D. are investigators in clinical trials sponsored by Gilead. The sponsors did not play any role in the design, methods, data collection, and analyses, or in the preparation of the present article.

The remaining authors report no conflicts of interest.

ABSTRACT

Treatment-naïve, noncirrhotic adults with chronic hepatitis C virus genotype 1 infection and with viremia levels <6 million IU/mL could be effectively treated with sofosbuvir/ledipasvir for 8 weeks. The aim of this pilot, prospective, open-label, multicenter study was to evaluate the efficacy and safety of this shortened treatment course in adolescents (≥12 years). The efficacy endpoint was sustained virological response 12 weeks after the end of treatment. Safety was assessed by adverse events and clinical/laboratory data. Fourteen consecutive adolescents (median age 16.5 years, Q1 14.1–Q3 17.4; female 57.1%), vertically infected, were enrolled and treated (June 2018–January 2019). Overall, the end of treatment response and sustained virological response 12 weeks after the end of treatment were 100%. No grade 3 to 4 adverse event or a serious adverse event was observed. Further studies are needed to confirm the optimal efficacy of the shortened 8-week treatment with sofosbuvir/ledipasvir for treatment-naïve, noncirrhotic adolescents with chronic hepatitis C virus genotype 1 infection and pretreatment viremia level < 6 million IU/mL.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.